Literature DB >> 3337850

Pharmacological modulation of cortisol secretion and dexamethasone suppression in Alzheimer's disease.

P Davous1, M Roudier, M L Piketty, C Abramowitz, Y Lamour.   

Abstract

We have investigated the dexamethasone suppression of cortisol release in a group of 28 patients with senile dementia of the Alzheimer type (SDAT) after stimulation by physostigmine and clonidine, as compared with basal conditions. All patients but one had previously been evaluated with a depression symptom checklist and had submitted to a standard Dexamethasone Suppression Test (DST). SDAT patients showed normal baseline cortisol values measured at 4:00 PM. DST was reproducible, but nonsuppression did not appear to be a feature of the disease, nor of the dementia syndrome, although a majority of the most demented patients were found to be nonsuppressors. Physostigmine stimulated cortisol secretion in 20 of 24 cases, irrespective of the severity of dementia. Clonidine induced a secretion in 12 of 15 cases, but this was less than that observed after cholinergic stimulation. Physostigmine made cortisol release significantly less sensitive to the suppressive effect of dexamethasone than clonidine in SDAT. This double response should be tested as a possible predictor of a cholinergic therapeutic effect.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3337850     DOI: 10.1016/0006-3223(88)90102-3

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  2 in total

1.  ACTH and cortisol secretion in patients with Alzheimer's disease.

Authors:  M Franceschi; L Airaghi; C Gramigna; G Truci; M G Manfredi; N Canal; A Catania
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-09       Impact factor: 10.154

2.  Dexamethasone effects on cortisol secretion in Alzheimer's disease: some clinical and hormonal features in suppressor and nonsuppressor patients.

Authors:  G Murialdo; A Barreca; F Nobili; A Rollero; G Timossi; M V Gianelli; F Copello; G Rodriguez; A Polleri
Journal:  J Endocrinol Invest       Date:  2000-03       Impact factor: 5.467

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.